
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
Stage: Clinical-stage biotechnology
Founded / HQ: 2020; San Diego, CA
Core tech: Physics-informed, AI-driven small-molecule discovery platform
Lead program: IAM1363 — brain-penetrant, selective Type II HER2 inhibitor in clinical studies
Funding: Series B > $150M (including $100M close + $50M extension); total funding reported ≈ $233M
Drug discovery and development for oncology and neuroscience
2020
Biotechnology Research
$53M
Participation from OrbiMed, Sequoia, Nexus Venture Partners and FreeFlow
$100M
Included new investors such as NVIDIA and Illumina Ventures
$50M
Series B now exceeds $150M; reported participation from Qatar Investment Authority
“Participation from a mix of life-science VCs, technology investors, and sovereign wealth funds (notable names reported: Ascenta Capital, Abingworth, Mubadala Capital, Exor Ventures, Qatar Investment Authority, Coatue, Catalio, Illumina Ventures, NVIDIA, Sequoia)”
| Company |
|---|